World Library  
Flag as Inappropriate
Email this Article

Antihypertensive drug

Article Id: WHEBN0000633467
Reproduction Date:

Title: Antihypertensive drug  
Author: World Heritage Encyclopedia
Language: English
Subject: Calcium channel blocker, Thiazide, Angiotensin II receptor antagonist, Renin inhibitor, ACE inhibitor
Collection: Antihypertensive Agents
Publisher: World Heritage Encyclopedia

Antihypertensive drug

Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure).[1] Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Evidence suggests that reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34%, of ischaemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.[2] There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used drugs are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta blockers.

Which type of medication to use initially for hypertension has been the subject of several large studies and resulting national guidelines. The fundamental goal of treatment should be the prevention of the important

  1. ^ Antihypertensive Agents at the US National Library of Medicine Medical Subject Headings (MeSH)
  2. ^ Law M, Wald N, Morris J; Wald; Morris (2003). "Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy" (PDF). Health Technol Assess 7 (31): 1–94.  
  3. ^ a b Nelson, Mark. "Drug treatment of elevated blood pressure". Australian Prescriber (33): 108–112. Archived from the original on 26 August 2010. Retrieved August 11, 2010. 
  4. ^ Nelson MR; McNeil JJ; Peeters A; et al. (Jun 4, 2001). "PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994–1998". Med J Aust 174 (11): 565–8.  
  5. ^ Wright JM, Musini VM (July 2009). Wright, James M, ed. "First-line drugs for hypertension". Cochrane Database of Systematic Reviews 8 (3): CD001841.  
  6. ^ p19
  7. ^ a b c d e f g h James, Paul A.; Oparil, Suzanne; Carter, Barry L.; Cushman, William C.; Dennison-Himmelfarb, Cheryl; Handler, Joel; Lackland, Daniel T.; LeFevre, Michael L.; MacKenzie, Thomas D.; Ogedegbe, Olugbenga; Smith, Sidney C.; Svetkey, Laura P.; Taler, Sandra J.; Townsend, Raymond R.; Wright, Jackson T.; Narva, Andrew S.; Ortiz, Eduardo (18 December 2013). "2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults". JAMA 311 (5): 507–20.  
  8. ^ Zillich AJ; Garg J; Basu S; et al. (August 2006). "Thiazide diretics, potassium and the development of diabetes: a quantitative review". Hypertension 48 (2): 219–224.  
  9. ^ Wang TJ, Ausiello JC, Stafford RS (20 April 1999). "Trends in Antihypertensive Drug Advertising, 1985–1996". Circulation 99 (15): 2055–2057.  
  10. ^ a b Wu, H.-Y.; Huang, J.-W.; Lin, H.-J.; Liao, W.-C.; Peng, Y.-S.; Hung, K.-Y.; Wu, K.-D.; Tu, Y.-K.; Chien, K.-L. (24 October 2013). "Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis". BMJ 347: f6008.  
  11. ^ a b Wright, Jr, Jackson T. (2002). "Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results From the AASK Trial". JAMA 288 (19): 2421.  
  12. ^ a b ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (December 18, 2002). "Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)".  
  13. ^ Leenen, F. H.H.; Nwachuku, C. E.; Black, H. R.; Cushman, W. C.; Davis, B. R.; Simpson, L. M.; Alderman, M. H.; Atlas, S. A.; Basile, J. N.; Cuyjet, A. B.; Dart, R.; Felicetta, J. V.; Grimm, R. H.; Haywood, L. J.; Jafri, S. Z.A.; Proschan, M. A.; Thadani, U.; Whelton, P. K.; Wright, J. T. (2006). "Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial". Hypertension 48 (3): 374–384.  
  14. ^ Verma S, Strauss M (November 2004). "Angiotensin receptor blockers and myocardial infarction: These drugs may increase myocardial infarction—and patients may need to be told".  
  15. ^ Strauss MH, Hall AS (August 2006). "Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox".  
  16. ^ Tsuyuki RT, McDonald MA (August 2006). "Angiotensin receptor blockers do not increase risk of myocardial infarction".  
  17. ^ Julius S, Kjeldsen SE, Weber M; et al. (June 2004). "Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial".  
  18. ^ Granger CB, McMurray JJ, Yusuf S; et al. (September 2003). "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial".  
  19. ^ Levy BI (September 2005). "How to explain the differences between renin angiotensin system modulators". Am. J. Hypertens. 18 (9 Pt 2): 134S–141S.  
  20. ^ Levy BI (January 2004). "Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system".  
  21. ^ Reudelhuber TL (December 2005). "The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous". Hypertension 46 (6): 1261–2.  
  22. ^ Lindholm LH, Carlberg B, Samuelsson O (29 Oct – 4 Nov 2005). "Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis".  
  23. ^ Carlberg B, Samuelsson O, Lindholm LH (6–12 Nov 2004). "Atenolol in hypertension: is it a wise choice?".  
  24. ^ Freemantle N; Cleland J; Young P; et al. (June 26, 1999). "β Blockade after myocardial infarction: systematic review and meta regression analysis".  
  25. ^ "Hypertension: management of hypertension in adults in primary care" (PDF).  
  26. ^ Sheetal Ladva (2006-06-28). "NICE and BHS launch updated hypertension guideline".  
  27. ^ ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (September 2003). "Diuretic Versus alpha-Blocker as First-Step Antihypertensive Therapy". Hypertension 42 (3): 239–46.  
  28. ^ a b Brunton L, Parker K, Blumenthal D, Buxton I (2007). "Therapy of hypertension". Goodman & Gilman's Manual of Pharmacology and Therapeutics. New York:  
  29. ^ a b Varon, J.; Marik, P. E. (Jul 2000). "The diagnosis and management of hypertensive crises" (Free full text). Chest 118 (1): 214–227.  
  30. ^ Vojnosanit, Pregl (2006). "Pattern of utilization of benzodiazepines in patients with hypertension: a pilot study".  
  31. ^ Chiou, L.C.; Ling, J.Y.; Chang, C.C. (September 1995). "Enhancement by benzodiazepines of the inhibitory effect of adenosine on skeletal neuromuscular transmission". Br J Pharmacol.  
  32. ^ Mehta, Akul (January 1, 2011). "Direct Renin Inhibitors as Antihypertensive Drugs". Retrieved 6 February 2014. 
  33. ^ a b c Chobanian AV; et al. (2003). "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report".  
  34. ^ Brown, MJ (2009). "Success and failure of vaccines against renin-angiotensin system components". Nature Reviews Cardiology 6 (10): 639–47.  
  35. ^ Wing LM; Reid CM; Ryan P; et al. (February 13, 2003). "A comparison of outcomes with angiotensin-converting—enzyme inhibitors and diuretics for hypertension in the elderly".  
  36. ^ Lewis PJ, Kohner EM, Petrie A, Dollery CT (1976). "Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment". Lancet 307 (7959): 564–566.  
  37. ^ Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT (1982). "Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up". Lancet 320 (8311): 1293–1295.  
  38. ^ Messerli FH, Williams B, Ritz E (2007). "Essential hypertension". Lancet 370 (9587): 591–603.  
  39. ^ "Section 11. Cardiovascular Disorders – Chapter 85. Hypertension". Merck Manual of Geriatrics. July 2005. 
  40. ^ a b "CG34 Hypertension – quick reference guide" (PDF).  
  41. ^ Williams B (November 2003). "Treatment of hypertension in the UK: simple as ABCD?". J R Soc Med 96 (11): 521–2.  
  42. ^ Würzner G,"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout." J Hypertens. 2001;19(10) 1855.
  43. ^ Worcester EM, Coe FL: Clinical practice. Calcium kidney stones" N Engl J Med 2010;363(10) 954-963.
  44. ^ 1.jac8/ysh 2014 guidlines not recommended betablockers as initial therapy for hypertension .Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-The JNC 7 Report. National Heart Lung and Blood Institute (NHLBI), 2003.
  45. ^ Rosendorff C, Black HR, Cannon CP, et al: Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention" Circulation 2007;115(21) 2761-2788.


See also

The JNC8 guidelines indicate reasons to choose one drug over the others for certain individual patients.[7]

  • Age can affect choice of medications. Current UK guidelines suggest starting patients over the age of 55 years first on calcium channel blockers or thiazide diuretics.
  • Anxiety may be improved with the use of beta blockers.
  • Asthmatics have been reported to have worsening symptoms when using beta blockers.
  • Benign prostatic hyperplasia may be improved with the use of an alpha blocker.
  • Chronic kidney disease. ACE inhibitors or ARBs should be included in the treatment plan to improve kidney outcomes regardless of race or diabetic status.[7][11]
  • Diabetes. The ace inhibitors and angiotensin receptor blockers have been shown to prevent the renal and retinal complications of diabetes mellitus.
  • Gout may be worsened by diuretics, while losartan reduces serum urate.[42]
  • Kidney stones may be improved with the use of thiazide-type diuretics [43]
  • Heart block. β-blockers and nondihydropyridine calcium channel blockers should not be used in patients with heart block greater than first degree. JNC8 does not recommend β-blockers as initial therapy for hypertension [44]
  • Heart failure may be worsened with nondihydropyridine calcium channel blockers, the alpha blocker doxazosin, and the alpha-2 agonists moxonidine and clonidine. Whereas β-blockers, diuretics, ACE inhibitors, angiotensin receptor blockers, and aldosterone receptor antagonists have been shown to improve outcome.[45]
  • Pregnancy. Although α-methyldopa is generally regarded as a first-line agent, labetalol and metoprolol are also acceptable. Atenolol has been associated with intrauterine growth retardation, as well as decreased placental growth and weight when prescribed during pregnancy. Ace inhibitors and angiotensin II receptor blockers (ARBs)are contraindicated in women who are or who intend to become pregnant.[33]
  • Race. JNC8 guidelines particularly points out that when used as monotherapy, thiazide diuretics and calcium channel blockers have been found to be more effective for reducing blood pressure in African-American patients than β-blockers, ACE inhibitors, or ARBs.[7]
  • Tremor may warrant the use of beta blockers.

The choice between the drugs is to a large degree determined by the characteristics of the patient being prescribed for, the drugs' side-effects, and cost. Most drugs have other uses; sometimes the presence of other symptoms can warrant the use of one particular antihypertensive. Examples include:

Patient Factors Affecting Antihypertensive Drug Choice

Current UK guidelines suggest starting patients over the age of 55 years and all those of African/Afrocaribbean ethnicity firstly on calcium channel blockers or thiazide diuretics, whilst younger patients of other ethnic groups should be started on ACE-inhibitors. Subsequently if dual therapy is required to use ACE-inhibitor in combination with either a calcium channel blocker or a (thiazide) diuretic. Triple therapy is then of all three groups and should the need arise then to add in a fourth agent, to consider either a further diuretic (e.g. spironolactone or furosemide), an alpha-blocker or a beta-blocker.[40] Prior to the demotion of beta-blockers as first line agents, the UK sequence of combination therapy used the first letter of the drug classes and was known as the "ABCD rule".[40][41]

Other drugs have a role in treating hypertension. Adverse effects of thiazide diuretics include hypercholesterolemia, and impaired glucose tolerance with increased risk of developing Diabetes mellitus type 2. The thiazide diuretics also deplete circulating potassium unless combined with a potassium-sparing diuretic or supplemental potassium. Some authors have challenged thiazides as first line treatment.[36][37][38] However as the Merck Manual of Geriatrics notes, "thiazide-type diuretics are especially safe and effective in the elderly."[39]

Thiazide diuretics are effective, recommended as the best first-line drug for hypertension by many experts, and are much more affordable than other therapies, yet they are not prescribed as often as some newer drugs. Hydrochlorothiazide is perhaps the safest and most inexpensive agent commonly used in this class and is very frequently combined with other agents in a single pill. Doses in excess of 25 milligrams per day of this agent incur an unacceptable risk of low potassium or Hypokalemia. Patients with an exaggerated hypokalemic response to a low dose of a thiazide diuretic should be suspected to have Hyperaldosteronism, a common cause of secondary hypertension.

A subsequent smaller study (ANBP2) did not show the slight advantages in thiazide diuretic outcomes observed in the ALLHAT study, and actually showed slightly better outcomes for ACE-inhibitors in older white male patients.[35]

The largest study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002, concluded that thiazide-type diuretics are better and cheaper than other major classes of drugs at preventing cardiovascular disease, and should be preferred as the starting drug. ALLHAT used the thiazide diuretic chlorthalidone.[12] (ALLHAT showed that doxazosin, an alpha-adrenergic receptor blocker, had a higher incidence of heart failure events, and the doxazosin arm of the study was stopped.)

If lifestyle changes are ineffective, then drug therapy is initiated, often requiring more than one agent to effectively lower hypertension. Which type of many medications should be used initially for hypertension has been the subject of several large studies and various national guidelines. Considerations include factors such as age, race, and other medical conditions.[33] In the United States, JNC8 (2014) recommends any drug from one of the four following classes to be a good choice as either initial therapy or as an add-on treatment: thiazide-type diuretics, calcium channel blockers, ACE inhibitors, or angiotensin II receptor antagonists.[7]

For mild blood pressure elevation, consensus guidelines call for medically supervised lifestyle changes and observation before recommending initiation of drug therapy. However, according to the American Hypertension Association, evidence of sustained damage to the body may be present even prior to observed elevation of blood pressure. Therefore the use of hypertensive medications may be started in individuals with apparent normal blood pressures but who show evidence of hypertension related nephropathy, proteinuria, atherosclerotic vascular disease, as well as other evidence of hypertension related organ damage.

Choice of initial medication

Blood pressure vaccinations are being trialed and may become a treatment option for high blood pressure in the future. CYT006-AngQb was only moderately successful in studies, but similar vaccines are being investigated.[34]

Blood pressure vaccines

Future treatment options

Bosentan belongs to a new class of drug and works by blocking the receptors of the hormone endothelin. It is specifically indicated only for the treatment of pulmonary artery hypertension in patients with moderate to severe heart failure.

Endothelin receptor blockers

For the most resistant and severe disease, oral minoxidil (Loniten) in combination with diuretic and β-blocker or other sympathetic nervous system suppressant may be used.

Some indirect anti-adrenergics are rarely used in treatment-resistant hypertension:

Adverse effects of this class of drugs include sedation, drying of the nasal mucosa and rebound hypertension.

Central alpha agonists lower blood pressure by stimulating alpha-receptors in the brain which open peripheral arteries easing blood flow. These alpha 2 receptors are known as autoreceptors which provide a negative feedback in neurotransmission (in this case, the vasoconstriction effects of adrenaline). Central alpha agonists, such as clonidine, are usually prescribed when all other anti-hypertensive medications have failed. For treating hypertension, these drugs are usually administered in combination with a diuretic.

Alpha-2 adrenergic receptor agonists

Aldosterone receptor antagonists are not recommended as first-line agents for blood pressure,[33] but spironolactone and eplerenone are both used in the treatment of heart failure.

Aldosterone receptor antagonists:

Aldosterone receptor antagonists

Renin comes one level higher than angiotensin converting enzyme (ACE) in the renin-angiotensin system. Inhibitors of renin can therefore effectively reduce hyptertension. Aliskiren (developed by Novartis) is a renin inhibitor which has been approved by the U.S. FDA for the treatment of hypertension.[32]

Renin Inhibitors

Although controversial over this off-label purpose, benzodiazepines may play a role in lowering blood pressure. They work as an agonist of the GABA-a receptors in the brain, thus slowing down neurotransmission and dilating blood vessels. GABA is an abbreviation for gamma-aminobutyric acid. It is an inhibitory neurotransmitter among others (glycine, adenosine, etc.) GABA-a receptors are ion channels that are the primary target for benzodiazepines. When an agonist binds to this receptor site, the protein channel opens, allowing negative chloride ions entering the channel and penetrating the voltage-gated ion site. Thus, giving negative feedback in neurotransmission and easing stress, anxiety and tension in patients that can be associated with elevated blood pressure.[30] In addition to GABA, benzodiazepines inhibit the re-uptake of a nucleoside chemical called Adenosine, which serves as an inhibitory chemical mentioned above. It also serves as a coronary vasodilator, allowing the cardiac muscle to relax and dilating cardiac arteries.[31]


Sodium nitroprusside, a very potent, short-acting vasodilator, is most commonly used for the quick, temporary reduction of blood pressure in emergencies (such as malignant hypertension or aortic dissection).[28][29] Hydralazine and its derivatives are also used in the treatment of severe hypertension, although they should be avoided in emergencies.[29] They are no longer indicated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in gestational hypertension.[28]

Vasodilators act directly on the smooth muscle of arteries to relax their walls so blood can move more easily through them; they are only used in hypertensive emergencies or when other drugs have failed, and even so are rarely given alone.


Despite lowering blood pressure, alpha blockers have significantly poorer endpoint outcomes than other antihypertensives, and are no longer recommended as a first-line choice in the treatment of hypertension.[27] However, they may be useful for some men with symptoms of prostate disease.

Although beta blockers lower blood pressure, they do not have a positive benefit on endpoints as some other antihypertensives.[22] In particular, beta-blockers are no longer recommended as first-line treatment due to relative adverse risk of stroke and new-onset of type 2 diabetes when compared to other medications,[3] while certain specific beta-blockers such as atenolol appear to be less useful in overall treatment of hypertension than several other agents.[23] A systematic review of 63 trials with over 35,000 participants indicated β-blockers increased the risk of mortality, compared to other antihypertensive therapies.[10] They do, however, have an important role in the prevention of heart attacks in people who have already had a heart attack.[24] In the United Kingdom, the June 2006 "Hypertension: Management of Hypertension in Adults in Primary Care"[25] guideline of the National Institute for Health and Clinical Excellence, downgraded the role of beta-blockers due to their risk of provoking type 2 diabetes.[26]

Propranolol, the first beta-blocker to be successfully developed

Adrenergic receptor antagonists

Indeed, as a consequence of AT1 blockade, ARBs increase Angiotensin II levels several-fold above baseline by uncoupling a negative-feedback loop. Increased levels of circulating Angiotensin II result in unopposed stimulation of the AT2 receptors, which are, in addition upregulated. Unfortunately, recent data suggest that AT2 receptor stimulation may be less beneficial than previously proposed and may even be harmful under certain circumstances through mediation of growth promotion, fibrosis, and hypertrophy, as well as proatherogenic and proinflammatory effects.[19][20][21]

The CHARM-alternative trial showed a significant +52% (p=0.025) increase in myocardial infarction with candesartan (versus placebo) despite a reduction in blood pressure.[18]

In the VALUE trial, the angiotensin II receptor blocker valsartan produced a statistically significant 19% (p=0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with amlodipine.[17]

Whether angiotensin receptor blockers may or may not increase the risk of myocardial infarction (heart attack) was announced in BMJ[14] and was debated in 2006 in the medical journal of the American Heart Association.[15][16] To date, there is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.

Angiotensin II receptor antagonists work by antagonizing the activation of angiotensin receptors.

Valsartan, an angiotensin II receptor antagonist

Angiotensin II receptor antagonists

However, ACE inhibitors (and angiotensin II receptor antagonists) should not be a first-line treatment for African-Americans without chronic kidney disease.[7] Results from the ALLHAT trial showed that thiazide-type diuretics and calcium channel blockers were both more effective as monotherapy in improving cardiovascular outcomes compared to ACE inhibitors for this subgroup.[12] Furthermore, ACE inhibitors were less effective in reducing blood pressure and had a 51% higher risk of stroke in African-Americans when used as initial therapy compared to a calcium channel blocker.[13]

A systematic review of 63 trials with over 35,000 participants indicated ACE inhibitors significantly reduced doubling of serum creatinine levels compared to other drugs (ARBs, α blockers, β blockers, etc.), and the authors suggested this as a first line of defense.[10] The AASK trial showed that ACE inhibitors are more effective at slowing down the decline of renal function compared to calcium channel blockers and beta blockers.[11] As such, ACE inhibitors should be the drug treatment of choice for patients with chronic kidney disease regardless of race or diabetic status.[7]

ACE inhibitors inhibit the activity of angiotensin-converting enzyme (ACE), an enzyme responsible for the conversion of angiotensin I into angiotensin II, a potent vasoconstrictor.

Captopril, the prototypical ACE inhibitor

ACE inhibitors

JNC8 recommends calcium channel blockers to be a first-line treatment either as monotherapy or in combination with thiazide-type diuretics, ACE inhibitors, or angiotensin II receptor antagonists for all patients regardless of age or race.[7]

Calcium channel blockers block the entry of calcium into muscle cells in artery walls.

Calcium channel blockers

In the United States, the JNC8 (Eighth Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) recommends thiazide-type diuretics to be one of the first-line drug treatments for hypertension, either as monotherapy or in combination with calcium channel blockers, ACE inhibitors, or angiotensin II receptor antagonists.[7] Despite thiazides being cheap and effective, they are not prescribed as often as some newer drugs. This is because they have been associated with increased risk of new-onset diabetes and as such are recommended for use in patients over 65 where the risk of new-onset diabetes is outweighed by the benefits of controlling systolic blood pressure.[8] Another theory is that they are off-patent and thus rarely promoted by the drug industry.[9]

Only the thiazide and thiazide-like diuretics have good evidence of beneficial effects on important endpoints of hypertension, and hence, should usually be the first choice when selecting a diuretic to treat hypertension. The reason why thiazide-type diuretics are better than the others is (at least in part) thought to be because of their vasodilating properties. Although the diuretic effect of thiazides may be apparent shortly after administration, it takes longer (weeks of treatment) for the full anti-hypertensive effect to develop.

Diuretics help the kidneys eliminate excess salt and water from the body's tissues and blood.

Hydrochlorothiazide, a popular thiazide diuretic



  • Diuretics 1
  • Calcium channel blockers 2
  • ACE inhibitors 3
  • Angiotensin II receptor antagonists 4
  • Adrenergic receptor antagonists 5
  • Vasodilators 6
  • Benzodiazepines 7
  • Renin Inhibitors 8
  • Aldosterone receptor antagonists 9
  • Alpha-2 adrenergic receptor agonists 10
  • Endothelin receptor blockers 11
  • Future treatment options 12
    • Blood pressure vaccines 12.1
  • Choice of initial medication 13
    • Patient Factors Affecting Antihypertensive Drug Choice 13.1
  • See also 14
  • References 15

[6] is recommended by NICE in the UK for those under 55 years old.ACE inhibitor are preferred first-line treatments for most people (from both efficacy and cost points of view), an thiazide-type diuretics and calcium channel blockers Although clinical evidence shows [5] of choice for high blood pressure when drugs are necessary.first-line treatment favors the thiazide diuretics as the evidence As of 2009, the best available [4] The several classes of antihypertensives differ in side effect profiles, ability to prevent endpoints, and cost. The choice of more expensive agents, where cheaper ones would be equally effective, may have negative impacts on national healthcare budgets.[3]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.